"Nitric Oxide Donors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A diverse group of agents, with unique chemical structures and biochemical requirements, which generate NITRIC OXIDE. These compounds have been used in the treatment of cardiovascular diseases and the management of acute myocardial infarction, acute and chronic congestive heart failure, and surgical control of blood pressure. (Adv Pharmacol 1995;34:361-81)
| Descriptor ID |
D020030
|
| MeSH Number(s) |
D27.505.519.656 D27.505.954.411.590
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Nitric Oxide Donors".
Below are MeSH descriptors whose meaning is more specific than "Nitric Oxide Donors".
This graph shows the total number of publications written about "Nitric Oxide Donors" by people in this website by year, and whether "Nitric Oxide Donors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 2 | 2 |
| 2004 | 1 | 3 | 4 |
| 2005 | 0 | 1 | 1 |
| 2006 | 1 | 1 | 2 |
| 2007 | 1 | 4 | 5 |
| 2008 | 1 | 0 | 1 |
| 2010 | 1 | 1 | 2 |
| 2011 | 1 | 1 | 2 |
| 2012 | 1 | 0 | 1 |
| 2013 | 0 | 1 | 1 |
| 2014 | 0 | 1 | 1 |
| 2015 | 2 | 0 | 2 |
| 2017 | 0 | 2 | 2 |
| 2018 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Nitric Oxide Donors" by people in Profiles.
-
Regulation of IL-10 and IL-17 mediated experimental autoimmune encephalomyelitis by S-nitrosoglutathione. Immunobiology. 2018 10; 223(10):549-554.
-
Distal Esophageal Spasm: A Review. Am J Med. 2018 09; 131(9):1034-1040.
-
Nitric oxide production by glomerular podocytes. Nitric Oxide. 2018 01 30; 72:24-31.
-
A Phase 2a dose-escalation study of the safety, tolerability, pharmacokinetics and haemodynamic effects of BMS-986231 in hospitalized patients with heart failure with reduced ejection fraction. Eur J Heart Fail. 2017 10; 19(10):1321-1332.
-
S-Nitrosoglutathione-mediated STAT3 regulation in efficacy of radiotherapy and cisplatin therapy in head and neck squamous cell carcinoma. Redox Biol. 2015 Dec; 6:41-50.
-
Design, synthesis, and antitumor evaluation of novel histone deacetylase inhibitors equipped with a phenylsulfonylfuroxan module as a nitric oxide donor. J Med Chem. 2015 May 28; 58(10):4325-38.
-
M1 polarization bias and subsequent nonalcoholic steatohepatitis progression is attenuated by nitric oxide donor DETA NONOate via inhibition of CYP2E1-induced oxidative stress in obese mice. J Pharmacol Exp Ther. 2015 Jan; 352(1):77-89.
-
Augmented dilation to nitric oxide in uterine arteries from rats with type 2 diabetes: implications for vascular adaptations to pregnancy. Am J Physiol Heart Circ Physiol. 2014 Feb 15; 306(4):H610-8.
-
S-nitrosoglutathione induces ciliary neurotrophic factor expression in astrocytes, which has implications to protect the central nervous system under pathological conditions. J Biol Chem. 2013 Feb 08; 288(6):3831-43.
-
S-nitrosoglutathione reduces oxidative injury and promotes mechanisms of neurorepair following traumatic brain injury in rats. J Neuroinflammation. 2011 Jul 06; 8:78.